(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market 'Fruzaqla', or fruquintinib, for the treatment of previously-treated metastatic colorectal cancer (CRC).

The AIM-traded firm said the approval was the first...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE